Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03091764 · ClinicalTrials.gov registry record
Evaluation of a Patient-Reported Symptom Index for NMIBC
A clinical trial, sponsored by University of Sydney.
- Completed
- Registry status
- 498
- Enrollment target
NCT03091764: Completed study, sponsored by University of Sydney.
NCT03091764 is a clinical trial that has completed, run by University of Sydney. The registered enrollment target is 498 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03091764 has completed, sponsored by University of Sydney.
- COMPLETED
- Registry status
- 498 participants
- Enrollment target
Study Summary
This project will develop and evaluate a patient-reported symptom index to assess the impact of treatment for non-muscle invasive bladder cancer on patient burden, toxicity, symptoms and side effects. The symptom index will provide a method for assessing treatments from the patient's perspective; help healthcare professionals make better informed treatment decisions, and provide a method to be able to effectively evaluate treatments for non-muscle invasive bladder cancer.
Primary Outcome
non-muscle invasive bladder cancer symptom index (questionnaire being developed and evaluated in this study)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 498 participants |
| Start Date | 2016-07-01 |
| Est. Completion | 2021-08-30 |
What the finished NCT03091764 record still lists
NCT03091764 is an observational study that tracks outcomes without assigning an intervention. The registered 498 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03091764 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03091764 about?
NCT03091764 is a clinical study titled "Evaluation of a Patient-Reported Symptom Index for NMIBC". This project will develop and evaluate a patient-reported symptom index to assess the impact of treatment for non-muscle invasive bladder cancer on patient burden, toxicity, symptoms and side effects. The symptom index will provide a method for assessing treatments from the patient's perspective; he...
What is the current status of trial NCT03091764?
This trial is currently completed. The enrollment target is 498 participants. The study started on 2016-07-01. Estimated completion is 2021-08-30.
Who is sponsoring clinical trial NCT03091764?
This trial is sponsored by University of Sydney, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04137900 · 499 participants · Phase 1
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
- NCT06733480 · 499 participants · NA
Innovating Physical Therapy: A Pilot Study on Band Connect's Impact on Compliance, Satisfaction, and Revenue
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- NCT05301816 · 497 participants · NA
PDN Post Market, Multicenter, Prospective, Global Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI